Targeting Cysteine Residues of Human Immunodeficiency Virus Type 1 Protease by Reactive Free Radical Species

Antioxidants and Redox Signaling

Volumn 1, Issue 1, 1999, Pages 105-112

  Basu, Amartya ^b   Sehajpal, Prabodh K ^a,b   Ogiste, Jason S ^b   Lander, Harry M ^b  

^a GURU NANAK DEV UNIVERSITY   (India)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

CYSTEINE; DRUG DERIVATIVE; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PENICILLAMINE; PROTEINASE; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; VASODILATOR AGENT;

ARTICLE; BACTERIUM; CELL INCLUSION; CHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; ENZYMOLOGY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; POLYACRYLAMIDE GEL ELECTROPHORESIS;

BACTERIA; CYSTEINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; INCLUSION BODIES; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROPRUSSIDE; PENICILLAMINE; RECOMBINANT PROTEINS; S-NITROSO-N-ACETYLPENICILLAMINE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; VASODILATOR AGENTS;

EID: 0033086234     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.1999.1.1-105     Document Type: Article

References (34)

1. BONHAM, C.A., LU, L., HUFFMAN, R.A., SIMMONS, R.L., and THOMSON, A.W. (1997). Nitric oxide production by dendritic cells is associated with impairment of T cell responses. Transplantation Proc. 29, 1116-1117.
2. BUKRINSKY, M.I., NOTTET, H.S.L.M., SCHMIDT-MAYEROVA, H., DUBROSKY, L., FLANAGAN, C.R., MULLINS, M., LIPTON, S.A., and GENDELMAN, H.E. (1995). Regulation of nitric oxide synthase activity in Human Immunodeficiency Virus type 1 (HIV-1)-infected monocytes: Implications for HIV-associated neurological disease. J. Exp. Med. 181, 733-745.
3. CHENG, Y-S.E., McGOWAN, M., KETTNER, C.A., SCHLOSS, J.V., ERICKSON-VIITANEN, S., and YIN, F.H. (1990). High-level synthesis of recombinant HIV-1 protease and the recovery of active enzyme from inclusion bodies. Gene 87, 243-248.
4. DAVIS, D.A., DORSEY, K., WINGFIELD, P.T., STAHL, S.J., KAUFMAN, J., FALES, H.M., and LEVINE, R.L. (1996). Regulation of HIV-1 protease activity through cysteine modification. Biochemistry 35, 2482-2488.
5. 19F NMR. J. Biol. Chem. 266, 20709-20713.
6. DUNN, B.M., GUSTCHINA, A., WALODAWER, A., and KAY, J. (1994). Subsite preferences of retroviral proteinases. Methods Enzymol. 241, 254-278.
7. FITZGERALD, P.M., McKEEVER, B.M., VANMIDDLESWORTH, J.F., SPRINGER, J.P., HEIMBACH, J.C., LEU, C.T., HERBER, W.K., DIXON, R.A., and DRAKE, P.L. (1990). Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and aceryl-pepstatin to 2.0-Å resolution. J. Biol. Chem. 265, 14209-14219.
8. GARNIER, L., RATNAR, L., ROVINSKI, B., CAO, S-H., and WILLS, J.W. (1998). Particle size determinants in the Human Immunodeficiency Virus Type 1 Gag protein. J. Virol. 72, 4667-4677.
9. GRIFFITHS, J.T., PHYLIP, L.H., KONVALINKA, J., STROP, P., GUSTCHINA, A., WLODAWER, A., DAVENPORT, T.J., BRIGGS, R., DUNN, B.M., and KAY, J. (1992). Different requirement for productive interaction between the active site of HW-1 proteinase and substrates containing hydrophobic*hydrophobic-or -aromatic*pro-cleavage sites. Biochemistry 31, 5193-5200.
10. GUSTAFSON, M.E., JUNGER, K.D., FOY, B.A., BAEZ, J.A., BISHOP, B.F., RANGWALA, S.H., MICHENER, M.L., LEIMGRUBER, R.M., HOUSEMAN, K.A., MUELLER, R.A., MATTHEWS, B.K., OLINS, P.O., GRABNER, R.W., and HERSHMAN, A. (1995). Large-scale production of HIV-1 protease from Escherichia coli using selective extraction and membrane fractionation. Prot. Exp. Purification 6, 512-518.
11. HENDERSON, L.E., BOWERS, M.A., SOWDER, R.C. 2nd, SERABYN, S.A., JOHNSON, D.G., BESS, J.W. Jr., ARTHUR, L.O., BRYANT, D.K., and FENSLAU, C. (1992). Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: Posttranslational modifications, proteolytic processing, and complete amino acid sequences. J. Virol. 66, 1856-1865.
12. KAPLAN, A.H., MANCHESTER, M., and SWANSTROM, R. (1994). The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J. Virol. 68, 6782-6786.
13. KARLSTROM, A.R., and LEVINE, R.L. (1991). Copper inhibits the protease from human immunodeficiency virus 1 by both cysteine-dependent and cysteine-independent mechanisms. Proc. Natl. Acad. Sci. USA 88, 5552-5556.
14. KARLSTROM, A.R., SHAMES, B.D., and LEVINE, R.L. (1993). Reactivity of cysteine residues in the protease from human immunodeficiency virus: Identification of a surface-exposed region which affects enzyme function. Arch. Biochem. Biophys. 304, 163-169.
15. LANDER, H.M. (1997). An essential role for free radicals and derived species in signal transduction. FASEB J. 11, 118-124.
16. LAPATTO, R., BLUNDELL, T., HEMMINGS, A., OVERINGTON, J., WILDERSPIN, A., WOOD, S., MERSON, J.R., WHITTLE, P.J., DANLEY, D.E., GEOGHEGAN, K.F., HAWRYLIK, S.J., LEE, S.E., SCHELD, K.G., and HOBART, P.M. (1989). X-ray analysis of HTV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes. Nature 342, 299-302.
17. MATAYOSHI, E.D., WANG, G.T., KRAFFT, G.A., and ERICKSON, J. (1989). Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science 247, 954-958.
18. MATTHEWS, J.R., BOTTING, C.H., PANICO, M., MORRIS, H.R., and HAY, R.T. (1996). Inhibition of NF-kappaB DNA binding by nitric oxide. Nucleic Acids Res. 24, 2236-2242.
19. McBRIDE, A.A., KLAUSNER, R.D., and HOWLEY, P.M. (1992). Conserved cysteine residue in the DNA-binding domain of the bovine papillomavirus type 1 E2 protein confers redox regulation of the DNA-binding activity in vitro. Proc. Natl. Acad. Sci. USA 89, 7531-7535.
20. MIRZA, U.A., CHAIT, B.T., and LANDER, H.M. (1995). Monitoring reactions of nitric oxide with peptides and proteins by electrospray ionization-mass spectrometry. J. Biol. Chem. 270, 17185-17188.
21. MOHR, S., STAMLER, J.S., and BRUNE, B. (1994). Mechanism of covalent modification of glyceraldehyde-3-phosphate dehydrogenase at its active site thiol by nitric oxide, peroxynitrite and related nitrosating agents. FEBS Lett. 348, 223-227.
22. NATHAN, C.F., and HIBBS, J.B. Jr. (1991). Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. Opin. Immunol. 3, 65-70.
23. NAVIA, M.A., FITZGERALD, P.M.D., McKEEVER, B.M., LEU, C-H., HEIMBACH, J.C., HERBER, W.K., SIGAL, I.S., DARKE, P.L., and SPRINGER, J.P. (1989). Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337, 615-620.
24. PARTIN, K, ZYBARTH, G., EHRLICH, L., DECROMBRUGGHE, M., WIMMER, E., and CARTER, C. (1991). Deletion of sequences upstream of the proteinase improves the proteolytic processing of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 88, 4776-4780.
25. PERSICHINI, T., COLASANTI, M., LAURO, G.M., and ASCENZI, P. (1998). Cysteine nitrosylation inactivates the HIV-1 protease. Biochem. Biophys. Res. Commun. 250, 575-576.
26. REICIN, A.S., OHAGEN, A., YIN, L., HOGLUND, S., and GOFF, S.P. (1996). The role of Gag in human immuno-deficiency virus type 1 virion morphogenesis and early steps on the viral life cycle. J. Virol. 70, 8645-8652.
27. STAMLER, J.S. (1994). Redox signaling: Nitrosylation and related target interactions of nitric oxide. Cell 78, 931-936.
28. STAMLER, J.S., SINGEL, D.J., and LOSCALZO, J. (1992). Biochemistry of nitric oxide and its redox-activated forms. Science 258, 1898-1902.
29. TAMAI, K., SHEN, H., TSUCHIDA, S., HATAYAMA, I., SATOH, K., YASUI, A., OIKAWA, A., and SATO, K. (1991). Role of cysteine residues in the activity of rat glutathione transferase P (7-7). Biochem. Biophys. Res. Commun. 179, 790-797.
30. TORRE, D., and FERRARIO, G. (1996). Immunological as-pects of nitric oxide in HIV-I infection. Med. Hypo. 47, 405-407.
31. WAN, M., TAKAG, M., LOH, B-N., XU, X-Z., and Imanaka, T. (1996). Autoprocessing: An essential step for the activation of HIV-1 protease. Biochem. J. 316, 569-573.
32. WANG, C-T., and BARKLIS, E. (1993). Assembly, processing, and infectivity of Human Immunodeficiency Virus Type 1 gag mutants. J. Virol. 67, 4264-4273.
33. WLODAWER, A., MILLER, M., JASKOLSKI, M., SATHYANARAYANA, B., BALDWIN, E., WEBBER, I., SELK, L.M., CLAWSON, L., SCHNEIDER, J., and KENT, S.B.H. (1989). Conservative folding in retroviral proteases: Crystal structure of a synthetic HTV-1 protease. Science 245, 616-621.
34. ZYBARTH, G., and CARTER, C. (1995). Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing. J. Virol. 69, 3878-3884.